Overview

A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide

Status:
Completed
Trial end date:
2021-01-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn more about how tirzepatide affects stomach emptying in overweight/very overweight participants. Participants include those without diabetes and those with type 2 diabetes. The study will last about 13 weeks for each participant, including screening.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Acetaminophen
Tirzepatide